Coeptis Therapeutics Inc (COEP) — Tangible Net Worth Ratio
Coeptis Therapeutics Inc (COEP) has a Tangible Net Worth Ratio of 90.7% as of September 2025. This metric is calculated by deducting intangible assets ($1.21 Million) from net assets ($13.02 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See COEP net asset value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Coeptis Therapeutics Inc Tangible Net Worth Ratio (2018–2024)
This chart shows how Coeptis Therapeutics Inc's Tangible Net Worth Ratio has changed across 6 annual periods from 2018 to 2024. As of September 2025, the ratio stands at 90.7%, reflecting net assets of $13.02 Million with intangible assets of $1.21 Million USD. Also explore COEP net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Coeptis Therapeutics Inc (2018–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Coeptis Therapeutics Inc from 2018 to 2024, covering 6 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Coeptis Therapeutics Inc (COEP) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 86.0% | $3.87 Million | $541.88K | $8.91 Million | ▲ +65.8 pp |
| 2023 | 20.2% | $4.45 Million | $3.55 Million | $7.92 Million | ▼ -79.8 pp |
| 2022 | 100.0% | $4.80 Million | $0.00 | $7.92 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $2.35 Million | $0.00 | $6.77 Million | ▲ +0.0 pp |
| 2019 | 100.0% | $15.69K | $0.00 | $171.54K | ▲ +0.0 pp |
| 2018 | 100.0% | $17.93K | $0.00 | $80.00K | — |